Doctor-to-patient transmission of hepatitis B virus: The potential of antiviral therapy for prevention

Scandinavian Journal of Gastroenterology, Supplement

Volumn 39, Issue 241, 2004, Pages 45-49

  Buster, E H C J ^a   Van Der Eijk, A A ^a   De Man, R A ^a   Schalm, S W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral therapy; HBV DNA; Health care workers; Hepatitis B virus; Lamivudine; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ADENOSINE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE TRANSMISSION; DOCTOR PATIENT RELATION; DRUG TOLERANCE; FLU LIKE SYNDROME; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; JOB PERFORMANCE; MEDICAL PRACTICE; PREGNANCY; PRIORITY JOURNAL; RISK; SEROCONVERSION; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; REVIEW;

ANTIVIRAL AGENTS; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; HEALTH PERSONNEL; HEPATITIS B, CHRONIC; HUMANS; VIRAL LOAD;

EID: 11144227639     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.1080/00855920410010997     Document Type: Conference Paper

References (39)

1. Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol. In press.
2. Department of Health. Health Service Circular 2000/020. NHS Executive. Hepatitis B-infected health care workers; 2000 (www.doh.gov.uk/nhsexec/ hepatitisb.htm).
3. Hofmann F, Hasselhorn HM. European and North American regulations on employing HBV-, HCV- and HIV-infected persons in health care. Chirurg 2000;71:396-403.
4. Inspectorate of Health. IGZ Bulletin. Prevention Iatrogenic Hepatitis B. The Hague; 2002 IGZ 02-001.
5. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989;1:406-10.
6. Anonymous. Outbreak of hepatitis B associated with an oral surgeon - New Hampshire. MMWR Morb Mortal Wkly Rep 1987;36:132-3.
7. Harpaz R, Von Seidlein L, Averhoff FM, Tormey MP, Sinha SD, Kotsopoulou K, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996;334:549-54.
8. Heptonstall J. Outbreaks of hepatitis B virus infection associated with infected surgical staff. CDR (Lond Engl Rev) 1991;1: R81-5.
9. The Incident Investigation Teams. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med 1997;336:178-84.
10. Prentice MB, Flower AJ, Morgan GM, Nicholson KG, Rana B, Firmin RK, et al. Infection with hepatitis B virus after open heart surgery. Br Med J 1992 304:761-4.
11. Anonymous. Acute hepatitis B associated with gynaecological surgery. Lancet 1980;1:1-6.
12. Carl M, Blakey DL, Francis DP, Maynard JE. Interruption of hepatitis B transmission by modification of a gynaecologist's surgical technique. Lancet 1982;1:731-3.
13. Lettau LA, Smith JD, Williams D, Lundquist WD, Cruz F, Sikes RK, et al. Transmission of hepatitis B with resultant restriction of surgical practice. JAMA 1986;255:934-7.
14. Hadler SC, Sorley DL, Acree KH, Webster HM, Schable CA, Francis DP, et al. An outbreak of hepatitis B in a dental practice. Ann Intern Med 1981;95:133-8.
15. Rimland D, Parkin WE, Miller GB, Jr, Schrack WD. Hepatitis B outbreak traced to an oral surgeon. N Engl J Med 1977;296: 953-8.
16. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA, 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385-93.
17. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;355:2237-44.
18. Okamoto M, Nagata I, Murakami J, Kaji S, Iitsuka T, Hoshika T, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000;182: 1511-4.
19. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
20. McIntyre J, Gray G. What can we do to reduce mother to child transmission of HIV? Br Med J 2002;324:218-21.
21. Duong T, Ades AE, Gibb DM, Tookey PA, Masters J. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. Br Med J 1999;319:1227-9.
22. van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000;32:1040-1.
23. Zonneveld M, Nunen AB, Niesters HG, Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7.
24. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002;359:1488-9.
25. Schalm SW, van Wijngaarden JK. Doctor-to-patient transmission of viral hepatitis B: is it a problem, is there a solution? J Viral Hepat 2000;7:245-9.
26. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
27. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
28. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
29. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-28.
30. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-5.
31. van Nunen AB, Janssen HL, Wolters LM, Niesters HG, de Man RA, Schalm SW. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? Antiviral Res 2001;52:139-46.
32. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumavate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-8.
33. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
34. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348: 808-16.
35. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
36. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-7.
37. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. Aids 2003;17:F7-10.
38. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
39. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-901.